
01/24/2025
Breaking News! Spravato has received U.S. FDA approval as the first and only monotherapy for adults with major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants. This approval follows a U.S. FDA priority review of data showing that SPRAVATO alone led to rapid and significantly greater improvement in depressive symptoms compared to a placebo, with effects noticeable as early as 24 hours!
For more information please check out the link in our Bio.